A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination
Latest Information Update: 09 Aug 2024
At a glance
- Drugs ABO 1020 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Abogen Biosciences
Most Recent Events
- 16 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 22 Dec 2022 According to ClinicalTrials.gov record, protocol has been amended to increase patient number from 30 to 15030, Phase has been changed from I/II to Phase II/III. Also tha trial focus has been changed to TU and AR.
- 15 Dec 2022 Planned number of patients changed from 30 to 15030.